Amedisys Q3 2024 Revenue Rises Amid Merger Talks
Company Announcements

Amedisys Q3 2024 Revenue Rises Amid Merger Talks

The latest update is out from Amedisys ( (AMED) ).

Amedisys, Inc. reported a rise in net service revenue for Q3 2024, reaching $587.7 million, up from $556.2 million in 2023, despite merger-related expenses impacting net income, which fell to $16.9 million from $26.0 million. Adjusted net income per diluted share increased slightly to $1.00, showcasing resilience amidst merger discussions with UnitedHealth Group. The company remains a leader in home healthcare, with significant nationwide partnerships and a focus on high-quality patient care.

See more data about AMED stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyUnitedHealth says ‘will vigorously defend against the DOJ’s overreaching’
TheFlyDOJ, state AGs sue to block UnitedHealth’s acquisition of Amedisys
TheFlyDepartment of Justice files suit to block UnitedHealth, Amedisys merger
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App